Treatment of heparin-induced thrombocytopenia

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 457-467

  Greinacher, Andreas ^a,b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Inst fur Immunol T   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; DANAPAROID; DEXTRAN; HEPARIN; HIRUDIN; IMMUNOGLOBULIN; WARFARIN;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HUMAN; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0032718061     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615866     Document Type: Conference Paper

References (123)

1. Hirsh J, Warkentin, TE, Raschke R, Granger C, Ohman EM, Dalen J. Heparin and low molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 1998;114:489S-510S.
2. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
3. Young E, Prins MH, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-643.
4. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: The non-immunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost. 1995;21:106-116.
5. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: Laboratory Studies. Blood. 1988;72:925-930.
6. Chong BH, Fawaz I, Chestermann CN, Berndt MC. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240.
7. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541.
8. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316:581-589.
9. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
10. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994c;71:247-251.
11. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
12. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost. 1998;79:1-7.
13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
14. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: A prospective study. Circulation. 1999;99:73-80.
15. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia: A prospective study. Blood. 1998;92:#1490 [abstract].
16. Warkentin TE, Greinacher, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
17. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
18. Markwardt F. Hirudin: The promising antithrombotic. Cardiovasc Drug Rev. 1992;10:211-232.
19. Hoog PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA. 1989;86:3619-3623.
20. Weitz JI, Hudoba M, Massel D, Marganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
21. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97:544-552.
22. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: Comparison with heparin and aspirin. Circulation. 1998;97:681-685.
23. Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Hemostasis. 1990;20:112-118.
24. Nowak G, Bucha E, Göck T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res. 1992;66:707-715.
25. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hammes WD, Rijnierse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. Thromb Haemost. 1994;72:685-692.
26. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardiopulmonary bypass. Thromb Haemost. 1997;77:920-925.
27. Nowak G, Bucha E. A new method for the therapeutical monitor-ing of hirudin. Thromb Haemost. 1993;69:1306.
28. Riess FC, Pötzsch B, Jäger K, Bleese N, Schaper W, Müller-Berghaus G. Elimination von rekombinantem Hirudin aus der Blutzirkulation mittels Hämofiltration. Hämostaseologie. 1997;17:200-204.
29. Butler KD, Dolan SL, Talbot MD, Wallis RB. Factor VII and DDAVP reverse the effect of recombinant desulphatohirudin (CGB 39393) on bleeding in the rat. Blood Coagul Fibrinolysis. 1993;4:459-464.
30. Bove CM, Casey B, Marder VJ. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost. 1996;75:471-475.
31. Ibbotson SH, Grant PJ, Kerry R, Findlay VS, Prentice CRM. The influence of infusions of 1-Desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of r-hirudin. Thromb Haemost. 1991;65:64-66.
32. Dickneite G, Friesen HJ, Kumpe G, Reers M. Reduction of rh induced bleeding in pigs by the administration of von Willebrand Factor. Platelets. 1996;7:283-290.
33. Dickneite G, Nicolay U, Friesen HJ, Reers M. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thromb Haemost. 1998;80:192-198.
34. Irami MS, Harvey JW, Sexon RG. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol. 1995;75:422-423.
35. Diehl KH, Römisch J, Hein B, Jessel A, Ronneberger H, Paques EP. Investigation of activated prothrombincomplex concentrate as potential hirudin antidote in animal models. Haemostasis. 1995;25:182-192.
36. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 1995;50:20-25.
37. Olbrich K, Wiersbitzky M, Wacke W, Eichler P, Zinke H, Schwock M, Möx B, Kraatz G, Motz W, Greinacher A. Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin). Blood Coagul Fibrinolysis. 1998;9:273-277.
38. Schmidt OH, Lang W. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. N Engl J Med. 1997;337:1389.
39. Eichler P, Olbrich K, Pötzsch B, Greinacher A. Anti-hirudin antibodies in patients treated with recombinant hirudin for more than five days, a prospective study. Thromb Haemost. 1997;(Supplement):PS 2014.
40. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood. 1989;73:1592-1596.
41. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org10172). Thromb Haemost. 1993;70:554-561.
42. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997;54:903-924.
43. Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis. 1992;22:58-65.
44. Danhof M, deBoer A, Magnani HM, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org10172). Hemostasis. 1992;22:73-84.
45. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998;35:26-34.
46. Magnani HN. Orgaran (danaparoid-sodium) use in the syndrome of heparin-induced thrombocytopenia. Proceedings of a workshop held in London, 1996 Nov 1. Platelets. 1997;8:74-81.
47. Carlsson LE, Santoso S, Baurichter G; Kroll H, Papenberg S, Eichler P, Westerdaal, NAC, Kiefel V, van de Winkel JGJ, Greinacher A. Heparin-induced thrombocytopenia: New insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood. 1998;92:1526-1531.
48. Greinacher A, Amiral J, Dummel V, Vissac AM, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia, comparison of platelet aggregation test, heparin-induced platelet activation (HIPA) test, and PF4/heparin ELISA. Transfusion. 1994;34:381-385.
49. ®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG (abstract). Blood. 1996;88(Suppl 1):626a.
50. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80:292-297.
51. Vun CM, Evans S, Chong BH. Cross-reactivity study of low-molecular weight heparins and heparinod in heparin-induced thrombocytopenia. Thromb Res. 1996;81:525-532.
52. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998;35(Suppl.4):17-25.
53. Tardy B, Tardy-Poncet B, Viallon A, Piot M, Mazet E. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses. Thromb Haemost. 1998;80:530.
54. Bell WR, Jr. Defibrinogenating enzymes. Drugs. 1997;54(Suppl.3):18-31.
55. Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin TE, Anderson DR, Turner C, Kelton JG. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood. 1991;78:2194-2197.
56. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
57. Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmacother. 1998;32:55-59.
58. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemost. 1992;67:545-549.
59. Copplestone A, Oscier DG. Heparin-induced thrombocytopenia in pregnancy. Brit J Haematol. 1987;65:248.
60. Meytes D, Ayalon H, Virag I, Weisbort Y, Zakut H. Heparin-induced thrombocytopenia and recurrent thrombosis in pregnancy. A case report. J Reprod Med. 1986;31:993-996.
61. Calhoun BC, Hesser JW. Heparin-associated thrombocytopenia with pregnancy: Discussion of two cases. Am J Obst Gynecol. 1987;156:964-966.
62. Henny CHP, ten Cate H, ten Cate JW, Prummel MF, Peters M, Büller HR. Thrombosis prophylaxis in an ATIII deficient pregnant women: application of a low molecular weight heparinoid. Thromb Haemost. 1986;55:301.
63. Van Besien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anticoagulant and heparin-induced thrombocytopenia: Management with a low molecular weight heparinoid. Thromb Res. 1991;62:23-29.
64. Greinacher A, Eckhardt T, Mußmann J, Mueller-Eckhardt C. Pregnancy complicated by heparin-associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res. 1993;71:123-126.
65. Potter C, Gill JC, Scott P, McFarland JG. Heparin-induced thrombocytopenia in a child. J Pediatr. 1992;121:135-138.
66. Klement D, Rammos S, Kries R von, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr. 1996;155:11-14.
67. Murdoch IA, Beattie RM, Siver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr. 1993;82:495-497.
68. Oriot D, Wolf M, Wood C, Brun P, Sidi D, Devictor D, Tchernia G, Huault G. Severe thrombocytopenia induced by heparin in an infant with acute myocarditis. Arch Fr Pediatr. 1990;47:357-359.
69. Schiffmann H, Unterhalt M, Harms K, Figulla HR, Völpel H, Greinacher A. Erfolgreiche Behandlung einer Heparin-induzierten Thrombozytopenie Typ II im Kindesalter mit rekombinantem Hirudin. Monatsschr Kinderheilkunde. 1997,145:606-612.
70. Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass in patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg. 1984;87:673-677.
71. Smith JP, Walls JT, Muscato MS, McCord ES, Worth ER, Curtis JJ, Silver D. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia. Anaesthesiology. 1985;62:363-365.
72. Makhoul RG, Greenberg CS, McCann RL. Heparin associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg. 1986;4:522-528.
73. Warkentin TE, Kelton JG. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT (abstract). Blood. 1998;92(Suppl. 1):182a.
74. Magnani HN, Beijering RJR, Ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus Inc. 1997:487-500.
75. Riess FC, Löwer C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, Pötzsch B. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. Thorac Cardiovasc Surg. 1995;110:265-267.
76. Riess FC, Pötzsch B, Bader K, Bleese N, Greinacher A, Löwer C, Madlener K, Müller-Bergbaus G. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg. 1996;10:386-388.
77. Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anaesthesiology. 1998;89:777-780.
78. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis. 1992;22:85-91.
79. Greinacher A, Drost W, Michels I, Leitl J, Gottsmann M, Kohl HJ, Glaser M, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Hematol. 1992a;64:40-42.
80. Greinacher A, Philippen KH, Kemkes-Matthes B, Möckl M, Mueller-Eckhardt C, Schaefer K. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: Successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant. 1993;8:1176-1177.
81. Von Bonsdorff M, Stiekema J, Harjanne A, Alapiesse U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Organs. 1990;13:103-108
82. Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant. 1997; 12:2750-2755.
83. Vanholder RC, Camez A, Veys N, Soria J, Mirshahi MC, Soria C, Ringoir S. Recombinant hirudin. A specific thrombin-inhibiting anticoagulant for hemodialysis. Kidney Int. 1994,45:1754-1759.
84. Van Wyk V, Badenhorst PN, Luus HG, Kotzé HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int. 1995;48:1338-1343.
85. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr. 1997;109:354-358.
86. Hempel S, Lubenow N, Greinacher A. Nierenersatztherapie unter r-hirudin (Refludan) bei Heparin-induzierter Thrombozytopenie Typ II. Infusionsther Transfusionsmed. 1998;25:5/7p.
87. Vanholder RC, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655.
88. Mehta DP, Yoder EL, Appel J Bergsman KL. Heparin-induced thrombocytopenia and thrombosis reversal with streptokinase. A case report and review of the literature. Am J Hematol. 1991;36:275-279.
89. Krueger SK, Andreas E, Weinand E. Thrombolysis in heparin-induced thrombocytopenia with thrombosis. Ann Intern Med. 1985;103:159.
90. Clifton GD, Smith MD. Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis. Clin Pharm. 1986;5:597-601.
91. Dieck JA, Rizo-Patron C, Unisa A, Mathur V, Massumi GA. A new manifestation and treatment alternative for heparin-induced thrombosis. Chest. 1998;98:1524-1526.
92. Sobel M, Adelman B, Szentpeterey S, Hofmann M, Posner MP, Jenvey W. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg. 1988;8:395-401.
93. Frame JN, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med. 1989;111:946-947.
94. Vender JS, Matthew EB, Silverman IM, Konoitz H, Dau PC. Heparin-associated thrombocytopenia: Alternative managements. Anesth Analg. 1986;65:520-522.
95. Nurden AT, Laroche-Traineau J, Jallu V, Broult J, Durrien C, Besse P, et al. Heparin-induced thrombocytopenia: Observation of the nature of the antibody activities and on the use of gammaglobulin concentrates in a patient with thrombotic complications. Thromb Haemost. 1991;65:796a.
96. Grau E, Linares M, Olaso MA, Ruvira J, Sanchis J. Heparin-induced thrombocytopenia response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol. 1992;39:312-313.
97. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York: Marcel Dekker, Inc. 1994:75-127.
98. Greinacher A, Liebenhoff U, Kiefel V, Presek P, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose i.v. IgG. Thromb Haemost. 1994;71:641-645.
99. Bouvier JL, Lefebre P, Villain P, Elias A, Durand JM, Juhan I, Serradigmigni A. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: Report on 4 cases. Thromb Res. 1988;51:335-336.
100. Brady J, Riccio JA, Yumen OH, Makary AZ, Greenwood SM. Plasmapheresis: A therapeutical option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol. 1991;96:394-397.
101. Nand S, Robinson JA. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol. 1988;28:204-206.
102. Thorp D, Canty A, Whiting J, Dart G, Lloyd JV, Duncan E, Gallus A. Plasma exchange and heparin-induced thrombocytopenia. Prog Clin Biol Res. 1990;337:521-522.
103. Manzano L, Yebra M, Vargas JA, Barbolla L, Alvarez-Mon M. Plasmapheresis in heparin-induced thrombocytopenia and thrombosis. Stroke. 1990;21:1236.
104. Poullin P, Pietri P, Lefevre P. Heparin-induced thrombocytopenia with thrombosis: Successful treatment with plasma exchange. Brit J Haematol. 1998;102:630-631.
105. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated anti-platelet antibodies. Arch Intern Med. 1989;149:2285-2287.
106. Gruel Y, Lermusiaux P, Lang M, Darnige L, Rupin A, Delahousse B, Guilmot JL, Leroy J. Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann Vasc Surg. 1991;5:552-555.
107. Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf. 1997;17:325-341.
108. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998;90:247-258.
109. Keularts IMLW, Béguin S, de Zwaan C, Hemker HC. Treatment with a GP IIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost. 1998;80:370-371.
110. Hérault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR 121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost. 1998;79:383-388.
111. Hérault JP, Lalé A, Savi P, Pflieger AM, Herbert JM. In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR121566, a newly developed GP IIb/IIIa antagonist. Blood Coagul Fibrinolysis. 1997;8:206-207.
112. Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost. 1998;80:989-993.
113. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR 121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost. 1998;80:326-331.
114. Polgar J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood. 1998;91:549-554.
115. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin aIIbb2 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res. 1997;89(2):137-146.
116. Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol. 1996;52: 90-95.
117. Hourellou MH, Conard J, Lecrubier C, Samama M, Roque D'Orbeostel O, de Fenoyl O et al. Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemost. 1984;51:134.
118. Gouault-Heilmann M, Huet Y, Adnot S, Contant G, Bonnet F, Intrator L, Payen D, Levent M. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis. 1987;17:134-140.
119. Leroy J, Leclerc MH, Delahousse B, Guerois C, Foloppe P, Gruel Y, Toulemonde F. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular weight heparin (CY216). Semin Thromb Hemost. 1985;11:326-329.
120. Kleinschmidt S, Ziegenfuß T, Seyfert UT, Greinacher A. Septisch-toxisches Herz-Kreislauf-Versagen als Folge einer Heparin-induzierten Thrombozytopenie mit "White-Clot-Syndrom." Anästhesiol Intensivmed Notfallmed Schmerzther. 1993;28:58-60.
121. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. N Engl J Med. 1976;295:237-241.
122. Cimo PL, Moake JL, Weinger RS, Ben-Menachem Y, Khalil KG. Heparin-induced thrombocytopenia: Association with a platelet aggregating factor and arterial thromboses. Am J Hematol. 1979;6:125-233.
123. Contreras M. The appropriate use of platelets: an update from the Edinburgh Consensus Conference. Br J Haematol. 1998;101(Suppl. 1):10-12.